search
Back to results

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Primary Purpose

Hypercholesterolemia

Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
ISIS 301012 or Placebo
ISIS 301012 or Placebo
ISIS 301012 or Placebo
ISIS 301012 or Placebo
ISIS 301012 or Placebo
Sponsored by
Kastle Therapeutics, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypercholesterolemia focused on measuring LDL-cholesterol, apoB-100, apoB-48

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: BMI >/= 25 to </= 32 kg/m^2 fasting stable LDL-cholesterol >/= 130 mg/dL (3.36 mmol/L) and triglycerides < 400 mg/dL (4.55 mmol/L) Females not of childbearing potential Exclusion Criteria: No endocrine, hematologic, renal, hepatic, metabolic, psychiatric, neurology, pulmonary or cardiovascular disease Subjects who test positive for hepatitis B, C or HIV Current diagnosis or known history of liver disease, such as acute or chronic hepatitis, liver cirrhosis, liver steatosis, or liver function abnormalities such as AST, ALT, GGT, or total bilirubin >/= 1.5 x ULN at Screening A systolic blood pressure >/= 160 mmHg or a diastolic blood pressure >/= 95 mmHg on 2 occasions during Screening Concomitant medications within 14 days of dosing, except hormone replacement therapy for post-menopausal women and acetylsalicylic acid or paracetamol dosed for fewer than five consecutive days Subject has taken any lipid-lowering drug within 30 days or five half-lives (of the lipid-lowering drug) whichever is longer, prior to Screening Alcohol or drug abuse within 2 years of Screening Donated blood (450 mL) within the 3 months prior to Screening or suffered significant blood loss equal to a blood donor portion Subject smokes > 10 cigarettes, or more than one pipe or one cigar per day

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

A

B

C

D

E

Arm Description

Slow load with every other week maintenance

Slow load with every other week maintenance

No load; once weekly maintenance

No load; once weekly maintenance

No load; once weekly maintenance

Outcomes

Primary Outcome Measures

Percent reduction in LDL-cholesterol from baseline

Secondary Outcome Measures

Percent reduction in apoB-100 from baseline
Percent change from baseline in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL and LP(a)
Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios

Full Information

First Posted
September 19, 2005
Last Updated
August 1, 2016
Sponsor
Kastle Therapeutics, LLC
Collaborators
Ionis Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00216463
Brief Title
Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels
Official Title
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 301012 Administered to Hypercholesterolemic Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
August 2005 (undefined)
Primary Completion Date
March 2007 (Actual)
Study Completion Date
August 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Kastle Therapeutics, LLC
Collaborators
Ionis Pharmaceuticals, Inc.

4. Oversight

5. Study Description

Brief Summary
The aim of this study is to assess the safety and tolerability of varying dose and load regimens of ISIS 301012 in people who have elevated LDL-cholesterol levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia
Keywords
LDL-cholesterol, apoB-100, apoB-48

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
Slow load with every other week maintenance
Arm Title
B
Arm Type
Experimental
Arm Description
Slow load with every other week maintenance
Arm Title
C
Arm Type
Experimental
Arm Description
No load; once weekly maintenance
Arm Title
D
Arm Type
Experimental
Arm Description
No load; once weekly maintenance
Arm Title
E
Arm Type
Experimental
Arm Description
No load; once weekly maintenance
Intervention Type
Drug
Intervention Name(s)
ISIS 301012 or Placebo
Intervention Description
200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
Intervention Type
Drug
Intervention Name(s)
ISIS 301012 or Placebo
Intervention Description
200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
Intervention Type
Drug
Intervention Name(s)
ISIS 301012 or Placebo
Intervention Description
300 mg subcutaneous injection - every week for 13 weeks
Intervention Type
Drug
Intervention Name(s)
ISIS 301012 or Placebo
Intervention Description
400 mg subcutaneous injection - every week for 13 weeks
Intervention Type
Drug
Intervention Name(s)
ISIS 301012 or Placebo
Intervention Description
200 mg subcutaneous injection - every week for 13 weeks
Primary Outcome Measure Information:
Title
Percent reduction in LDL-cholesterol from baseline
Time Frame
14 days post dosing
Secondary Outcome Measure Information:
Title
Percent reduction in apoB-100 from baseline
Time Frame
14 days post dosing
Title
Percent change from baseline in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL and LP(a)
Time Frame
14 days post dosing
Title
Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios
Time Frame
14 days post dosing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: BMI >/= 25 to </= 32 kg/m^2 fasting stable LDL-cholesterol >/= 130 mg/dL (3.36 mmol/L) and triglycerides < 400 mg/dL (4.55 mmol/L) Females not of childbearing potential Exclusion Criteria: No endocrine, hematologic, renal, hepatic, metabolic, psychiatric, neurology, pulmonary or cardiovascular disease Subjects who test positive for hepatitis B, C or HIV Current diagnosis or known history of liver disease, such as acute or chronic hepatitis, liver cirrhosis, liver steatosis, or liver function abnormalities such as AST, ALT, GGT, or total bilirubin >/= 1.5 x ULN at Screening A systolic blood pressure >/= 160 mmHg or a diastolic blood pressure >/= 95 mmHg on 2 occasions during Screening Concomitant medications within 14 days of dosing, except hormone replacement therapy for post-menopausal women and acetylsalicylic acid or paracetamol dosed for fewer than five consecutive days Subject has taken any lipid-lowering drug within 30 days or five half-lives (of the lipid-lowering drug) whichever is longer, prior to Screening Alcohol or drug abuse within 2 years of Screening Donated blood (450 mL) within the 3 months prior to Screening or suffered significant blood loss equal to a blood donor portion Subject smokes > 10 cigarettes, or more than one pipe or one cigar per day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Genzyme, a Sanofi Company
Official's Role
Study Director
Facility Information:
City
Berlin
ZIP/Postal Code
D-14050
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
21593041
Citation
Akdim F, Tribble DL, Flaim JD, Yu R, Su J, Geary RS, Baker BF, Fuhr R, Wedel MK, Kastelein JJ. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011 Nov;32(21):2650-9. doi: 10.1093/eurheartj/ehr148. Epub 2011 May 18.
Results Reference
derived

Learn more about this trial

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

We'll reach out to this number within 24 hrs